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Abstract
Resveratrol is a plant-derived polyphenol that extends lifespan and healthspan in model organism. Despite extensive
investigation, the biological processes mediating resveratrol’s effects have yet to be elucidated. Because repression of
translation shares many of resveratrol’s beneficial effects, we hypothesized that resveratrol was a modulator of protein
synthesis. We studied the effect of the drug on the H4-II-E rat hepatoma cell line. Initial studies showed that resveratrol
inhibited global protein synthesis. Given the role of the mammalian Target of Rapamycin (mTOR) in regulating protein
synthesis, we examined the effect of resveratrol on mTOR signaling. Resveratrol inhibited mTOR self-phosphorylation and
the phosphorylation of mTOR targets S6K1 and eIF4E-BP1. It attenuated the formation of the translation initiation complex
eIF4F and increased the phosphorylation of eIF2a. The latter event, also a mechanism for translation inhibition, was not
recapitulated by mTOR inhibitors. The effects on mTOR signaling were independent of effects on AMP-activated kinase or
AKT. We conclude that resveratrol is an inhibitor of global protein synthesis, and that this effect is mediated through
modulation of mTOR-dependent and independent signaling.
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Introduction
Resveratrol is a plant-derived polyphenol found in grapes, red
wine, and other foods. This compound extends the lifespan of
lower organisms (yeast, worms, flies and fish) [1–3] and protects
rodents from a variety of age-related diseases, including cancer,
cardiovascular disease, obesity and diabetes [4–8]. Resveratrol is
considered a mimetic for some of the beneficial effects of caloric
restriction (reduction of food intake without malnutrition), which is
the only environmental intervention known to extend longevity in
a wide range of organisms [9,10].
A relationship between extended longevity and decreased
translation has been observed in a variety of conditions, including
caloric restriction [11,12] and inhibition of the nutrient–sensing
kinase termed mTOR (mammalian Target of Rapamycin) [11,13–
18]. In fact, recent studies have shown that continuous
administration of rapamycin, a specific inhibitor of mTOR
Complex 1 (mTORC1), increases lifespan in mice [19] and flies
[18]. mTORC1 is one of the two complexes, the other being
mTORC2, that account for signaling via mTOR. mTORC1
responds to growth factors, cellular energy and nutrient status by
stimulating, among other processes, the initiation of mRNA
translation [20]. This involves mTORC1-mediated phosphoryla-
tion of the eukaryotic initiation factor 4E-binding protein 1
(eIF4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). Phos-
phorylation of eIF4E-BP1 leads to its release from the cap-binding
factor eIF4E, thereby upregulating cap-dependent translation
[21]. Loss of function of eIF4E-BP or S6K1 retards the aging
process in flies and mice [12,17,18], suggesting that attenuation of
signaling through a single mTOR target is sufficient to extend
longevity.
mTOR signaling can be activated in response to the serine-
threonine kinase AKT. In response to insulin, phosphatidylinosi-
tol-3 kinase (PI3K) is activated, leading to the activation of
phosphoinositide-dependent kinase-1 (PDK-1), which in turn
phosphorylates AKT at Thr 308. Resulting activation of AKT
inhibits the formation of the tuberous sclerosis comple/2 (TSC)
and de-represses mTORC1 activity [22]. Conversely, low cellular
energy levels suppress mTORC1 activity via activation of AMP-
activated kinase a (AMPKa). AMPKa activation mediates TSC2
phosphorylation, which results in down regulation of mTORC1
activity [22]. In addition, AMPKa is also able to directly
phosphorylate the mTORC1 binding partner Raptor [23].
Interestingly, metformin, an activator of AMPK signaling [22],
has been shown to increase longevity and decelerate cancer
formation in mice [24,25].
Among the human disorders that involve dysregulation of
mTOR signaling is cancer. Until recently, rapamycin was the only
known mTOR inhibitor. However, the acquired resistance of
many tumors to rapamycin prompted studies that led to the recent
discovery of other mTOR inhibitors [26], including Torin1 and
pp242. These inhibitors target the mTOR kinase itself, thereby
blocking signal transduction by both mTORC1 and mTORC2.
Until now, the effects of resveratrol and mTOR signaling on
longevity and cancer have been considered independent, although
mTOR signaling has been shown to be involved in both [11,13–
18,27–31]. In the present studies, we examined the effect of
resveratrol on the control of protein synthesis and the activation of
mTORC1 targets in rat hepatoma cells. Our results show that
resveratrol can inhibit global translation in association with
signaling effects that are both mTORC1-dependent and indepen-
dent, thus providing a potential link between control of protein
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related disease states.
Results
Resveratrol inhibits protein translation in rat hepatoma
cells
High concentrations of resveratrol can induce lysis of human
hepatic cells [32]. To avoid such toxicity as a confounding factor,
we first determined the maximum resveratrol concentration at
which viability of the H4-II-E cells was maintained. Concentra-
tions of resveratrol ranging from 0.01 mM to 500 mM were
examined for effects on cell viability. Concentrations up to 5 mM
were not associated with changes in cell adherence or morphology.
Higher concentrations caused cells to round up and release from
the surface of the cell culture plate. Through the use of cell counts
and the vital dye trypan blue, we confirmed that 5 mM resveratrol
was not associated with reduced cell proliferation or cell viability
(Figure 1A).
To determine the effect of resveratrol on protein synthesis, we
measured the incorporation of radiolabeled leucine into protein
over a time course ranging from 0 to 6 h.
14C-Leu incorporation
was significantly decreased after cells were treated with 5 mM
resveratrol for 4 and 6 h with the value at 2 h not quite reaching
statistical significance (Figure 1B). This was interpreted as
evidence for a consistent effect of resveratrol on protein synthesis
that increased in magnitude with increased duration of exposure.
In a repeat experiment in which cells were incubated for 6 h
with
3H-Leu and resveratrol, protein synthesis was inhibited
by approximately 50% when normalized for DNA content
(Figure 1C). DNA content was not significantly affected by
resveratrol.
One potential caveat in the interpretation of global protein
synthesis measurements would be an effect of resveratrol on the
transport of leucine into the cell. To test this, cells were exposed to
resveratrol for 1 h prior to incubation with
3H-Leu for 5, 10 and
15 minutes. At these short time points,
3H-Leu incorporation into
protein is minimal. In two experiments, cell content of
3H-Leu was
not significantly affected by resveratrol (Figure S1A), indicating the
absence of an effect on leucine transport. In a separate experiment,
cells were incubated with
3H-Leu for 24 h. The media was
removed, the cells were washed, and resveratrol or vehicle was
added.
3H-Leu remaining in protein was determined after 6 h.
Results showed that resveratrol did not affect protein degradation
(Figure S1B).
Resveratrol inhibits mTOR-mediated phosphorylation
events
Having determined that resveratrol inhibits protein synthesis in
H4-II-E cells, and given the central role of mTOR in translation
control, we went on to examine the effect of resveratrol on mTOR
signaling. Cells were treated with resveratrol, rapamycin, a specific
inhibitor of mTORC1, or pp242, an inhibitor of mTOR kinase
activity [26]. Cells were lysed after 1 h. Extracts were analyzed by
Western immunoblotting.
Resveratrol, rapamycin and pp242 all decreased the phosphor-
ylation of mTOR at a known self-phosphorylation site, Ser 2481
(Figure 2A). Similarly, phosphorylation of S6K1 at an mTOR-
dependent site (Thr 389 in the human protein), was inhibited by
all three agents (Figure 2B). Phosphorylation of 4E-BP1 at
mTOR-dependent sites (Thr 37/46) was reduced significantly,
though less markedly, by resveratrol, rapamycin and pp242
treatment (Figure 2C).
Figure 1. Effect of resveratrol on cell proliferation, viability,
and protein synthesis. Panel A: H4-II-E hepatoma cells were
incubated with DMSO vehicle (control), or resveratrol for 6 hr, at the
end of which time total cell number and percentage of dead cells were
determined by trypan blue staining and counting. Panel B: Cells were
incubated with DMSO vehicle (control; filled circles), or resveratrol
(unfilled circles) and
14C-Leu for 0, 2, 4 or 6 h. At the end of these
incubation periods, cell lysates were prepared and analyzed for
radiolabeled leucine incorporation into protein. Data, shown as the
mean 6 SD. *P,0.05 versus control as determined by ANOVA. Panel C:
3H-Leu incorporation was similarly determined after a 6 h incubation
period. Results, normalized to DNA content, are shown as the mean 6
SD. *P,0.05 versus control as determined by ANOVA.
doi:10.1371/journal.pone.0029513.g001
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Initiation of mRNA translation, the primary determinant of
translation efficiency, requires the assembling of eukaryotic
initiation factors (eIFs) into the multiprotein complex eIF4F.
eIF4F includes the cap-recognition factor eIF4E and the scaffold
protein eIF4G [33]. To determine if resveratrol affects the
formation of the eIF4F complex, cells were incubated with
resveratrol, rapamycin or pp242 for 1 h. Cell lysates were
subjected to 7mGTP affinity purification of the eIF4F complex.
Resveratrol decreased the amount of eIF4G bound to eIF4E
(Figure 3). This decrease was similar in magnitude to that observed
Figure 3. The effect of resveratrol and mTOR inhibitors on the
formation of the eIF4F translation initiation translation
complex. H4-II-E hepatoma cells were incubated with vehicle (control),
resveratrol, rapamycin or pp242 for 1 h. eIF4E-containing complexes
were purified from cell lysates using 7mGTP-Sepharose beads. The
affinity purified proteins were analyzed by Western immunoblotting
using antibodies against eIF4E and eIF4G. Representative immunoblots
are shown above the graph. The immunoblots were quantified by
densitometry to obtain a ratio of eIF4G to eIF4E for each condition. In
order to compare results across experiments, results were expressed as
percent of control for each individual experiment and are shown as the
mean and standard error of the mean for triplicate determinations.
doi:10.1371/journal.pone.0029513.g003
Figure 2. Effect of resveratrol and mTOR inhibitors on mTOR-
mediated phosphorylation. H4-II-E hepatoma cells were incubated
with DMSO vehicle (control), resveratrol, rapamycin or pp242 for 1 h.
Cell lysates were prepared and analyzed by Western immunoblotting.
The results of triplicate immunoblots were quantified by densitometry.
Data were normalized between blots by analyzing a single control
sample on all blots. The results shown in the graphs represent the ratio
of phospho:total mTOR (Panel A), S6K1 (Panel B) and eIF4E-BP1 (Panel
C). Representative immunoblots are shown below each graph. Results
are shown as the mean 6 SD. *P,0.05 versus control as determined by
ANOVA.
doi:10.1371/journal.pone.0029513.g002
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exposure to pp242.
We also examined the phosphorylation of eIF4G1 in the affinity
purified eIF4F complexes. Resveratrol exposure was associated
with a modest decrease in phosphorylation at Ser 1108, a site that
has been shown to be mTORC1-dependent [34] (data not shown).
Resveratrol–mediated inhibition of mTOR signaling
cannot be attributed to effects on AMPK and AKT
signaling
Signaling through mTORC1 is modulated in response to
upstream signaling involving AMPK and AKT [22]. To assess the
effect of resveratrol on these upstream kinases, cell lysates
prepared from H4-II-E cells treated with resveratrol were analyzed
by Western immunoblotting.
We first examined AMPKa (Figure 4A). Using the serum-
containing media that were employed for our experiments,
phosphorylation of AMPKa was not affected significantly by
0.5 mM of aminoimidazole carboxamide ribonucleotide (AICAR),
an AMPKa agonist. Although higher concentrations of AICAR
decreased cell viability (data not shown), phosphorylation of
AMPKa could be induced by exposure to 0.5 mM of AICAR
under serum-free conditions without evidence of cell toxicity, as
previously reported [35]. In neither condition was phosphorylation
of AMPKa at Thr172 increased in response to resveratrol.
Furthermore, resveratrol did not significantly increase phosphor-
ylation of acetyl-CoA carboxylase, a marker of AMPKa signaling
(Figure 4B).
We went on to study signaling involving AKT (Figure 5). Under
basal conditions, AKT phosphorylation at the PDK1-dependent
Thr308 site was minimal. This was particularly apparent when
contrasted with results obtained with cells exposed to 100 nM of
insulin for 5 min. The low level of AKT phosphorylation under
basal conditions precluded the detection of an inhibitory effect of
resveratrol. To determine if resveratrol inhibits the phosphoryla-
tion of AKT at Thr308 upon insulin stimulation, we incubated
cells with resveratrol or the PI3K inhibitor LY294002 as a control
[36]. Insulin-induced phosphorylation of AKT at Thr308 was not
reduced significantly by resveratrol. As expected, LY294002
blocked insulin-induced AKT Thr308 phosphorylation. We
interpreted these results as indicating that under the conditions
employed to examine the effect of resveratrol on basal (non-
stimulated) protein synthesis and mTORC1 signaling, AKT was
not active. We concluded that inhibition of AKT was not a viable
explanation for the aforementioned resveratrol effects.
Resveratrol does not disrupt mTORC1
Major components of mTORC1 include mTOR itself, raptor
and mLST8 [22]. Inhibition of mTORC1 signaling by rapamycin
is associated with dissociation of raptor from mTOR [37,38].
Given that the upstream kinases AKT and AMPKa did not
appear to be involved in resveratrol’s inhibition of mTORC1, we
compared its effect on mTORC1 to that of rapamycin. mTOR
was immunoprecipitated from cells exposed to resveratrol and
rapamycin. Raptor content in the immunoprecipitated complex
was determined by immunoblotting (Figure 6 and Figure S3).
Consistent with previous findings [37,38], rapamycin decreased
the amount of the raptor:mTOR complex. This effect was not
seen with resveratrol.
Although the interpretation of immunoprecipitation kinase
assays for mTOR is complicated owing to the multi-protein
complexes in which mTOR resides, we considered the direct
inhibition of mTOR kinase activity by resveratrol to be an
important mechanism to explore. Using recombinant 4E-BP1 as a
phosphate acceptor, we measure kinase activity in mTOR
immunoprecipitates from cells cultured under control conditions
or exposed to resveratrol. Results (not shown) indicated no effect of
resveratrol on mTOR kinase activity.
Effect of resveratrol on eIF2a phosphorylation
Phosphorylation of eIF2a inhibits the ability of the eIF2
complex to deliver the charged methionyl initiator tRNA to the
initiation codon, thereby downregulating translation initiation
[39]. eIF2a phosphorylation is mediated by multiple kinases,
including GCN2. Those enzymes are not targets of mTOR.
Resveratrol increased eIF2a phosphorylation at Ser 51 (Figure 7).
In contrast, rapamycin had no effect while pp242 exposure was
associated with a decrease in phosphorylation.
Discussion
While limited information is available regarding the tissue
uptake of resveratrol, it is known that the liver plays a key role in
the metabolism of dietary polyphenols, including resveratrol.
Despite the high absorption of resveratrol administered orally to
humans, resveratrol bioavailability is low because it is rapidly
metabolized in liver via glucuronate and sulfate conjugation [40].
In fact, unmetabolized resveratrol has a relatively short half life
[41]. It has been suggested, therefore, that in vitro investigations of
resveratrol biological effects should focus on resveratrol conjugates
[42]. Due to the abundance of resveratrol conjugates in rat
hepatocytes after incubation with resveratrol [43], we consider
hepatic cells to be an advantageous model system for the
investigation of resveratrol effect. Additionally, hepatic cells take
up resveratrol by both passive diffusion and active transport [44].
This may account for the fact that our experiments used
resveratrol at ten to twenty times lower concentrations than
generally used in other types of cells, such as human embryonic
kidney cells [45], cardiac myocytes [46], HeLa cells [47] and
mouse embryonic fibroblasts [47].
Hepatoma cells are also a relevant model because resveratrol
has been proposed as a chemopreventative agent for human
hepatocellular carcinoma [48,49] a disease in which the mTOR
pathway is often constitutively activated [50]. However, the
mechanisms by which resveratrol affects cancer development and/
or progression remain uncertain [8,51–53].
Inhibition of translation is known to affect numerous physio-
logical functions, including the stress response and oncogenic
signaling [54,55] Interestingly, dietary restriction has been shown
to have a dramatic effect on tumor suppression in almost every
tumor tested [56] with the exception of tumors with activated
PI3K [57]. In addition, dietary restriction [9,10] and mTOR
inhibition, related conditions owing to the biological function of
mTOR, increase longevity in a number of model systems. These
include yeast [15], worms [11,13,16] , flies [14,18,58] and
mammals [19]. Because resveratrol can extend lifespan in animals
and repression of mTOR is associated with retarded aging, we
hypothesized that resveratrol could modulate protein synthesis,
perhaps through effects on mTOR signaling or other well-
characterized mechanisms involved in the control of translation.
Our data support this hypothesis.
Our initial studies demonstrated that resveratrol induces a
modest inhibition of global translation in H4-II-E hepatic cells. The
magnitude of this effect is similar to that observed by us using
rapamycin [59]. Resveratrol-induced reduction of global protein
synthesis in the H4-II-E cells was independent of any change in cell
number or cell viability. Our results identified multiple signaling
Resveratrol Modulates Protein Translation
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e29513Figure 4. The effect of resveratrol on AMPK activation. Panel A: H4-II-E hepatoma cells were incubated with DMSO vehicle (control), resveratrol
or AICAR for 1 h in serum containing media (left) or serum free media (right). Cell lysates were analyzed by immunoblotting for total and
phosphorylated AMPKa. Panel B: Cells were incubated with DMSO vehicle (control) or resveratrol for 1 h. Samples were analyzed for acetyl CoA
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mTOR activity (as indicated by the mTOR self-phosphorylation
site), formation of the eIF4F cap-binding complex, phosphorylation
of eIF4G1, and phosphorylation of eIF2a. The last of these effects
was not recapitulated by rapamycin, a finding that distinguishes the
signaling effects of resveratrol and from those of mTORC1-specific
of generalmTOR inhibition. It should be noted that our findings do
not rule out other effects of resveratrol on translation initiation. In
fact, eIF4A has been recently suggested as a direct target of
resveratrol binding in vitro [60].
The regulation of mTOR signaling is highly complex. It
involves large, multi-protein complexes and input from an array of
upstream signals [22]. Studies to date have led to the
characterization of two mTOR-containing complexes, mTORC1
and mTORC2. The former is known to account for mTOR-
mediated translation control and rapamycin sensitivity. Unlike
rapamycin, resveratrol did not affect the binding between raptor, a
component of mTORC1, and mTOR. On the other hand, we
found decreased mTOR self-phosphorylation at Ser 2481. This
suggested that resveratrol may directly inhibit mTOR kinase
activity, a possibility that was not supported by results of
immunoprecipitation kinase assays. However, resveratrol may
interact with other components of the mTORC1 complex or
modulate the activity of other mTOR effectors. Among these are
the upstream kinases AMPK and AKT [61]. The former is
especially interesting since AMPK-deficient mice have been
described to be resistant to the metabolic effects of resveratrol
[62]. However, our studies implicate neither AMPK nor AKT
signaling in resveratrol-induced inhibition of mTORC1 signaling.
In the case of AMPK, the basis for our results may lie in the
high sensitivity of H4-II-E cells to resveratrol. We performed our
studies at 5 mM, a concentration of resveratrol that did not affect
cell proliferation or viability. Concentrations of resveratrol
reported to activate AMPK are more than twice those used in
our experiments [61,63–65]. In addition, H4-II-E cells seem to be
particularly resistant to AMPK activation under basal conditions,
since nutrient stress (elimination of serum from culture media) was
required for AICAR to activate AMPK. Similarly, the basal level
of AKT phosphorylation at Thr308, the PDK1 site, was minimal
in H4-II-E cells. This was most apparent when compared to cells
exposed to insulin, indicating that inhibition of AKT activity is
unlikely to account for any of the effects of resveratrol that we
observed. An inhibitory effect of resveratrol on phosphorylation of
AKT at Ser 473 has been previously observed [66]. Our results
indicate that this could be due to an effect of resveratrol on mTOR
signaling. However, the inhibitory effect of resveratrol on
translation that we observed was seen under basal, not insulin-
stimulated, conditions.
A commonly cited mechanism of resveratrol action is the
activation of the NAD
+-dependent protein deacetylase SIRT1
carboxylase (ACC) phosphorylation and content. The positions of the a and b ACC isoforms are shown to the right of representative immunoblots.
For both panels, the results of triplicate immunoblots were quantified by densitometry. Results are shown as the mean 6 SD. *P,0.05 versus control
as determined by ANOVA.
doi:10.1371/journal.pone.0029513.g004
Figure 5. The effect of resveratrol on AKT phosphorylation and the stability of mTORC1. H4-II-E hepatoma cells were incubated with
DMSO vehicle (control), resveratrol or LY294002 for 1 h. Where noted, cells were stimulated with insulin 5 min prior to cell lysis. Cell lysates were
analyzed by Western immunoblotting for total and phosphorylated AKT at Thr 308. The results of triplicate immunoblots were quantified by
densitometry. Data were normalized between blots by analyzing a single control sample on all blots. The results are shown as the mean 6 SD.
*P,0.05 versus control as determined by ANOVA.
doi:10.1371/journal.pone.0029513.g005
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SIRT1 may be of particular importance. The molecular
mechanism of resveratrol action through activation of SIRT1
remains to be elucidated [1,67,68]. In fact, recent studies suggest
that resveratrol-mediated effects in vivo may be independent of a
direct activation of SIRT1 [69,70]. More recently, SIRT1 was
implicated as a regulator of mTOR signaling [47]. In these studies,
SIRT1-deficient Hela cells and mouse embryonic cells were shown
to have elevated phosphorylation of S6K1 and 4EB-P1. However,
these investigators found that resveratrol could decrease the
phosphorylation of the S6K1 target ribosomal protein S6 in cells
depleted of SIRT1, although it did so with less efficiency under
these conditions [47]. In other studies implicating S6K1 in the
mechanism of resveratrol action [45], the effect was again found to
be independent of SIRT1. We have performed preliminary studies
showing that the inhibition of S6K1 phosphorylation by
resveratrol in hepatic cells was not affected by the SIRT1 inhibitor
EX527 (Figure S2A). Likewise, EX527 did not block the effect of
resveratrol on the phosphorylation of 4EBP1 and mTOR (data not
shown). EX527 has been used by numerous investigators as a
selective inhibitor of SIRT1 deacetylase at concentrations similar
to those that we employed [66,71–73]. However, we were unable
to validate an effect of EX527 on SIRT1 in H4-II-E cells. In an
attempt to do so, we studied the expression and acetylation of
several SIRT1 targets, PGC1a, FoxO1 and p53. Only p53 was
detectable by Western blotting under basal conditions (Figure
S2B). We detected no acetylation of this or any other SIRT1 target
in the presence of EX527 despite employing a variety of
conditions. Therefore, we are unable to draw any definitive
conclusions regarding the efficacy of EX527 or the role of SIRT1
in the effects we observed. During the preparation of this
manuscript, an inhibitory effect of resveratrol on insulin and
leucine stimulated mTOR signaling was described in mouse
fibroblasts [74]. This effect was found to be independent of Sirt1
activation, instead involving changes in the interaction of mTOR
and its inhibitor DEPTOR.
The nutrient-sensing mTOR pathway has emerged as a link
between nutrient availability, translation control, longevity and
oncogenesis [11,13–18,27–29,58]. Our findings identify resvera-
trol as a modulator of protein synthesis, translation initiation and
elongation factors, and mTOR signaling. Any or all of these effects
could contribute to the anti-aging and anti-carcinogenic properties
of resveratrol. Furthermore, we have found that resveratrol
decreases mTOR-dependent phosphorylation, although resvera-
trol and mTOR inhibitors show different effects on the
phosphorylation of eIF2a. This increase in eIF2a phosphorylation
induced by resveratrol is of particular interest given the ability of
amino acid restriction to induce this same effect [75]. Considered
in light of the role of amino acids in modulating mTOR signaling
[33], we propose that resveratrol may regulate translation through
mechanisms similar to those that sense reduced amino acid
availability. The use of an immortalized cell line as a model system
has limitations with regard to physiologic significance, so in vivo
studies will be needed to more definitively address the role of




Antibodies to mTOR, phospho-mTOR, S6K1, phospho-S6K1,
phospho-eIF4E-BP1, eIF4E, AMPKa, phospho-AMPKa, acetyl
CoA carboxylase, phospho-acetyl CoA carboxylase, raptor,
phospho-eIF2a, acetylated lysine, acetylated-p53, AKT, and
phospho-AKT were purchased from Cell Signaling Technology
(Danvers, MA, USA.). Antibodies to eIF4E-BP1, eIF4G1, p53,
FoxO1, PGC1a, and eIF2a were purchased form Santa Cruz
Biotechnology (Santa Cruz, CA, USA.). Protein A-Sepharose CL-
4B and 7-methyl-GTP (7mGTP)-Sepharose 4B were purchased
form GE Healthcare (Piscataway, NJ, USA.). Resveratrol was a
Figure 6. The effect of resveratrol and rapamycin on integrity
of mTORC1. Cell lysates were analyzed by immunoprecipitation of
mTOR followed by immunoblotting for raptor and mTOR. A second
replicate experiment yielded similar results (Figure S3).
doi:10.1371/journal.pone.0029513.g006
Figure 7. The effect of resveratrol and mTOR inhibitors on
eIF2a. H4-II-E hepatoma cells were incubated with DMSO vehicle
(control), resveratrol, rapamycin or pp242 for 1 h. Cell lysates were
analyzed by Western immunoblotting to determine the ratio of
phospho:total eIF2a. A representative immunoblot is shown below
the graph. The results are shown as the mean 6 SD. *P,0.05 versus
control as determined by ANOVA.
doi:10.1371/journal.pone.0029513.g007
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USA.). Rapamycin was purchased from LC Laboratories
(Woburn, MA, USA.). pp242 was purchased from Chemdea
(Ridgewood, NJ, USA.). EX527 was purchased form TOCRIS
Bioscience (Ellisville, MO, USA).
3H-Leu (specific activity: 100 to
150 Ci/mmol ) and
14C-Leu (specific activity .300 mCi/mmol)
were purchased from Dupont/New England Nuclear (Boston,
MA, USA). The Quant-iT PicoGreenH dsDNA Assay Kit was
purchased from Invitrogen Corporation (Carlsbad, CA, USA.).
Protein was quantified using the BCA Protein Assay Kit from
Thermo Scientific (Rockford, IL, USA.)
Biochemical analyses
H4-II-E cells [76] were cultured in Minimal Essential Medium
Gibco # 4100-034 (Carlsbad, CA, USA) with 5% Fetal Bovine
Serum. The composition of the media, including amino acid
content, can be found at http://www.invitrogen.com/site/us/en/
home/support/Product-Technical-Resources/media_formulation.
99.html. In particular, leucine was present at a concentration of
0.397 mM for all experiments. Resveratrol, rapamycin, pp242 and
EX527 were dissolved in 100% DMSO. Control conditions used
equivalent DMSO concentrations.
Protein synthesis was measured as the incorporation of
3H-Leu
or
14C-Leu into protein [59]. Cells were plated in six well plates
(2610
5 per well) and allowed to attach overnight. Resveratrol and
radiolabeled leucine (1 mCi/ml) were added and allowed to
incubate for designated time periods prior to cell lysis. Where
noted, results were normalized to DNA content, which was
measured using the fluorescent Quant-iT PicoGreenH dsDNA
Assay Kit with lDNA (0–500 ng/ml) as standard.
For leucine uptake experiments, cells were incubated with
resveratrol (5 mM) for 1 h prior to addition of
3H-Leu (1 mCi/ml).
Cells were lysed after 5, 10 or 15 min. Correction for non specific
uptake was made by determining the amount of radiolabeled
leucine retained in the extracellular space or cell surface after
incubation of
3H-Leu for 10 seconds. Protein degradation was also
assessed, using the method of [77,78]. To do so,
3H-Leu was
added to the cells for 24 h. Cells were washed with fresh media
and incubated with resveratrol. After 6 h of incubation, cells were
washed twice with cold PBS and precipitated with 10%
trichloracetic acid (TCA). The percentage of protein degraded
over 6 h treatment was calculated as 100D/(D+E+F) where D is
the total cpm in the TCA precipitated fraction, E is the total cpm
in the TCA non precipitated fraction, and F is the total cpm in the
resveratrol media and PBS washes.
Western immunoblotting was carried out as previously
described [59,79]. For 7mGTP cap-binding studies, Western
immunoblotting and mTOR immunoprecipitation, cells (2610
6
per well) were allowed to attach overnight to 10 cm plates.
Resveratrol (5 mM), rapamycin (100 nM) [56], pp242 (100 nM)
[80] and EX527 (1 mMo r5mM) were added to cells for 1 h. In
experiments where cells were serum deprived, cells were
transferred to serum-free media and exposed to resveratrol
(5 mM) or AICAR (0.5 mM) for 1 h. In experiments where cells
were stimulated with insulin, cells were incubated with resveratrol
(5 mM) or LY294002 (10 mM) for 1 h and exposed to insulin
(100 nM) for 5 min prior cell lyses.
For 7mGTP cap-binding analysis, cell lysates were prepared
and analyzed as previously described [80]. For mTOR immuno-
precipitation, cells were lysed in 0.3% Chaps buffer [38] and
sonicated 2 times for 10 seconds. After pre-clearing with protein
A-Sepharose CL-4B, 400 mg of cell lysate protein was incubated
overnight with mTOR antibody. A 1:1 suspension of protein A-
Sepharose CL-4B (50 ml) in 0.3% Chaps buffer was added to the
sample and incubated for 3 h at 4uC. Immunoprecipitates were
washed with 0.3% Chaps buffer four times, and samples were
resolved and analyzed by immunoblotting.
Statistical analyses
Except where noted, data are shown as the mean and standard
deviation. Two-way comparisons were performed using the
unpaired t-test. Analysis of variance with a Tukey post hoc test
was used in cases of multiple comparisons. Differences were
considered significant at p,0.05. Experiments were indepen-
dently repeated at least twice with three biological replicates each
time.
Supporting Information
Figure S1 The effect of resveratrol on leucine uptake
and protein degradation. Panel A: Leucine uptake. H4-II-E
hepatoma cells were incubated with resveratrol for 1 h prior to
addition of
3H-Leu. Cells were lysed after 5, 10 or 15 min.
Correction for non specific uptake was made by determining the
amount of radiolabeled leucine retained in the extracellular space
or cell surface after incubation of
3H-Leu for 10 seconds.
P=0.119 at 15 minutes. Panel B: Protein degradation was assessed
by measuring the uptake and subsequent release of
3H-Leu.
3H-
Leu was added to the cells for 24 h. Cells were washed with fresh
media and incubated with resveratrol or vehicle control. After 6 h
of incubation, cells were washed twice with cold PBS and
precipitated with 10% trichloracetic acid (TCA). The percentage
of protein degraded over 6 h treatment was calculated as 100D/
(D+E+F) where D is the total cpm in the TCA precipitated
fraction, E is the total cpm in the TCA non precipitated fraction,
and F is the total cpm in the resveratrol media and PBS washes.
The results are shown as the mean 6 SD. *P,0.05 versus control
as determined by ANOVA.
(TIF)
Figure S2 The effect of EX527 on the effect of resver-
atrol. Panel A: H4-II-E hepatoma cells were incubated for 1 h
with DMSO vehicle or resveratrol (5 mM) in the presence of 0, 1
or 5 mM EX527. Cell lysates were analyzed by immunoblotting
for total and phosphorylated S6K1. The Western immunoblots
were quantified by densitometry to determine the ratio of
phospho:total S6K1. A representative immunoblot is shown below
the graph. The results are shown as the mean 6 SD. *P,0.05
versus control as determined by ANOVA. Panel B: The cell lysates
prepared for the experiment shown in Panel A were analyzed by
immunoprecipitation of p53 followed by Western immunoblotting
for acetylated and total p53.
(TIF)
Figure S3 Independent repetition of the effect of
resveratrol and rapamycin on integrity of mTORC1.
Cell lysates were analyzed by immunoprecipitation of mTOR
followed by immunoblotting for raptor and mTOR.
(TIF)
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